BiotechTube

Metronidazole + Metronidazole-DRF1 + Metronidazole-DRF2

Phase 2Completed
1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Clostridium Difficile Associated Diarrhea

Conditions

Clostridium Difficile Associated Diarrhea

Trial Timeline

Mar 1, 2012 → Mar 1, 2013

NCT ID
NCT01559545

About Metronidazole + Metronidazole-DRF1 + Metronidazole-DRF2

Metronidazole + Metronidazole-DRF1 + Metronidazole-DRF2 is a phase 2 stage product being developed by Dr. Reddy's Laboratories for Clostridium Difficile Associated Diarrhea. The current trial status is completed. This product is registered under clinical trial identifier NCT01559545. Target conditions include Clostridium Difficile Associated Diarrhea.

What happened to similar drugs?

9 of 20 similar drugs in Clostridium Difficile Associated Diarrhea were approved

Approved (9) Terminated (5) Active (11)
✅Fidaxomicin + Vancomycin + PlaceboAstellas PharmaApproved
✅Fidaxomicin + VancomycinAstellas PharmaApproved
✅Fidaxomicin + VancomycinMerckApproved
✅Vancomycin + FidaxomicinMerckApproved
✅bezlotoxumab + Vancomycin OralMerckApproved
✅Fidaxomicin 200 mg + Placebo + VancomycinMerckApproved
✅BezlotoxumabMerckApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01559545Phase 2Completed

Competing Products

20 competing products in Clostridium Difficile Associated Diarrhea

See all competitors
ProductCompanyStageHype Score
Fidaxomicin + Vancomycin + PlaceboAstellas PharmaApproved
35
Fidaxomicin + Treatment for CDI other than fidaxomicin TypeAstellas PharmaPre-clinical
26
OPT-80 + vancomycinAstellas PharmaPhase 3
40
Fidaxomicin oral suspension + Fidaxomicin tablets + Vancomycin oral liquid + Vancomycin capsulesAstellas PharmaPhase 3
40
Fidaxomicin + VancomycinAstellas PharmaApproved
43
Fidaxomicin + VancomycinMerckApproved
43
fidaxomicin + PlaceboMerckPhase 3
40
Surotomycin + PlaceboMerckPhase 1
29
CB-183,315 + Placebo + VancomycinMerckPhase 2
35
Surotomycin + PlaceboMerckPhase 1
29
MK-6072 + MK-3415A + Placebo + SOCMerckPhase 3
40
Vancomycin + FidaxomicinMerckApproved
43
FidaxomicinMerckPre-clinical
18
Bezlotoxumab + Standard CDI treatmentMerckPre-clinical
26
MK-3415 + MK-6072 + MK-3415A + Placebo + SOCMerckPhase 3
40
Fidaxomicin + Vancomycin + Matching Placebo to FidaxomicinMerckPhase 3
40
bezlotoxumab + Vancomycin OralMerckApproved
43
Bezlotoxumab + Placebo + Antibacterial drug treatment (ABD)MerckPhase 3
40
Bezlotoxumab Injection [Zinplava]MerckPre-clinical
26
PAR-101/OPT-80 + VancomycinMerckPhase 3
40